GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
K

K Pharma 4896.T · JPY

Health Care · Tokyo Stock Exchange · 🇯🇵 Japan

Compare

657

+6.83%

Close of 9 Nov 2026, in JPY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About K Pharma

Its shares trade on Tokyo Stock Exchange under the ticker 4896.T. It has been listed since 17 October 2023. In the fiscal year to 31 December 2023, it reported revenue of ¥1.00bn and net income of ¥260.3m. At that date it held total assets of ¥3.31bn and shareholders' equity of ¥3.10bn.

K Pharma Inc is a JP-based company operating in Pharmaceuticals industry. The company is headquartered in Minato-Ku, Tokyo-To. The company went IPO on 2023-10-17. K Pharma Inc is a Japan-based company mainly engaged in the pharmaceutical business. The firm operates through a single segment of research, development, manufacture, and sale of pharmaceuticals, among others. The firm is engaged in induced pluripotent stem cell (iPS) drug discovery business. Neural progenitor cells, the cells that form the basis of nerves, are created from iPS cells, cryopreserved, and then 200000 cells are transplanted by injection into the site of a patient's spinal cord injury. The firm is also engaged in the research, development, manufacture and sale of regenerative medicine products.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
17 Oct 2023
Employees
13

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • K Pharma Inc's iPS cell technology enables precise spinal cord injury treatments with 200,000 cells per injection.
  • The company focuses on regenerative medicine products within the Pharmaceuticals sector.
  • K Pharma Inc operates a single segment covering R&D, manufacturing, and sales of pharmaceuticals.

Weaknesses

  • K Pharma Inc has only 13 full-time employees, limiting operational capacity.
  • The company's IPO on 17 October 2023 indicates limited market presence.
  • K Pharma Inc's single-segment business model lacks diversification.

Opportunities

  • The growing demand for regenerative medicine in Japan's Health Care sector presents opportunities.
  • K Pharma Inc can expand its iPS cell applications in spinal cord injury treatments.
  • The Pharmaceuticals industry in Japan continues to show strong growth potential.

Threats

  • K Pharma Inc faces competition from established pharmaceutical companies in Japan.
  • Regulatory challenges in the Health Care sector may impact product approvals.
  • The limited employee count of 13 could hinder rapid response to market changes.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.